艾力斯：公司创新药品被纳入新版国家医保目录

Core Viewpoint - The company艾力斯 has announced that its innovative drugs,甲磺酸伏美替尼片 (brand name "艾弗沙", abbreviated as "伏美替尼") and 枸橼酸戈来雷塞片 (brand name "艾瑞凯", abbreviated as "戈来雷塞"), have been included in the National Medical Insurance Catalog for 2025, which is a significant development for the company's market position and potential revenue growth [1] Group 1 - The drug伏美替尼 has been retained in the National Medical Insurance Catalog for first-line and second-line treatment indications after negotiations [1] - The drug戈来雷塞 has been included in the National Medical Insurance Catalog for second-line treatment indications for the first time through negotiation [1]